Butyrate Greatly Enhances Derivation of Human Induced Pluripotent Stem Cells by Promoting Epigenetic Remodeling and the Expression of Pluripotency-Associated Genes

Stem Cell Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Stem Cells (Impact Factor: 6.52). 04/2010; 28(4):713-20. DOI: 10.1002/stem.402
Source: PubMed


We report here that butyrate, a naturally occurring fatty acid commonly used as a nutritional supplement and differentiation agent, greatly enhances the efficiency of induced pluripotent stem (iPS) cell derivation from human adult or fetal fibroblasts. After transient butyrate treatment, the iPS cell derivation efficiency is enhanced by 15- to 51-fold using either retroviral or piggyBac transposon vectors expressing 4 to 5 reprogramming genes. Butyrate stimulation is more remarkable (>100- to 200-fold) on reprogramming in the absence of either KLF4 or MYC transgene. Butyrate treatment did not negatively affect properties of iPS cell lines established by either 3 or 4 retroviral vectors or a single piggyBac DNA transposon vector. These characterized iPS cell lines, including those derived from an adult patient with sickle cell disease by either the piggyBac or retroviral vectors, show normal karyotypes and pluripotency. To gain insights into the underlying mechanisms of butyrate stimulation, we conducted genome-wide gene expression and promoter DNA methylation microarrays and other epigenetic analyses on established iPS cells and cells from intermediate stages of the reprogramming process. By days 6 to 12 during reprogramming, butyrate treatment enhanced histone H3 acetylation, promoter DNA demethylation, and the expression of endogenous pluripotency-associated genes, including DPPA2, whose overexpression partially substitutes for butyrate stimulation. Thus, butyrate as a cell permeable small molecule provides a simple tool to further investigate molecular mechanisms of cellular reprogramming. Moreover, butyrate stimulation provides an efficient method for reprogramming various human adult somatic cells, including cells from patients that are more refractory to reprogramming.

Download full-text


Available from: Robert Brodsky
  • Source
    • "Neurological Huntington's Disease (HD) Fibroblasts[69]Parkinson's Disease (PD) Fibroblasts[70]Familial Alzheimer's Disease (AD) Fibroblasts[71]Frontotemporal Dementia (FTD) Fibroblasts[72]Amyotrophic Lateral Sclerosis (ALS) Fibroblasts737475Spinocerebellar Ataxia Type 2 (SCA 2) Fibroblasts[76]Machado-Joseph Disease (MJD) Fibroblasts[77]Rett Syndrome Fibroblasts[78]Cardiac/ Muscular LEOPARD Syndrome Fibroblasts[79]Duchenne Muscular Dystrophy (DMD) Fibroblasts[80]Long QT Syndrome Fibroblasts[81]Pompe Disease Fibroblasts[82]Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Fibroblasts[83,84]Dilated Cardiomyopathy (CMD) Fibroblasts[85]Barth Syndrome (BTHS) Fibroblasts[86]Friedreich Ataxia Fibroblasts[87]Metabolic Alpha-1 Antitrypsin Deficiency (A1ATD) Fibroblasts[88]Familial Hypercholesterolemia (FH) Fibroblasts[89]Glycogen Storage Disease Type 1a (GSD1a) Fibroblasts[90]Glycogen Storage Disease Type 1b (GSD1b) Fibroblasts, Hepatic Cells (nonparenchymal)[91]Type 1 Diabetes Fibroblasts[92]Gauchers Disease (GD) Fibroblasts[93]Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) Fibroblasts[94]Carnitine Palmitoyltransferase II (CPT II) Fibroblasts[95]Eye/Retina Usher Syndrome (USH) Keratinocytes[96]Retinitis Pigmentosa (RP) Fibroblasts979899Leber Congenital Amaurosis (LCA) Fibroblasts[100]Gyrate Atrophy (GA) Fibroblasts[101]Best Vitelliform Macular Dystrophy (BVMD) Fibroblasts[102]Age Related Macular Degeneration (AMD) T-Cells[103]Blood Shwachman-Diamond Syndrome (SDS) Fibroblasts[104]Dyskeratosis Congenita (DKC) Fibroblasts[105]Familial Platelet Disorder (FPD) Peripheral T Cells[106]Sickle Cell Disease MSCs[107,108]β-Thalassemia Fibroblasts[109]Myeloproliferative Disorders (MPDs) Peripheral Blood CD34 + Cells[18]Myelodysplastic Syndromes (MDS) Hematopoietic Cells[17][20,116]Juvenile Myelomonocytic Leukemia (JML) Primary JML Cells[117]Gastrointestinal Cancer Gastrointestinal Cancer Cells[21]Li-Fraumeni Syndrome (LFS) Fibroblasts[118]Other Hutchinson Gilford Progeria Fibroblasts[119]Primary Ovarian Insufficiency (POI) Fibroblasts[120]Hermansky-Pudlak (HP) Fibroblasts[121]Chediak-Higashi (CH) Fibroblasts[121]iPSCs technology is providing exciting new opportunities in cardiovascular research by creating platforms to study the mechanisms of disease pathogenesis that could lead to new therapies. For instance, iPSCs derived from patients with LEOPARD syndrome, an autosomal-dominant developmental disorder caused by mutation in the PTPN11 gene encoding the SHP2 phosphatase, can recapitulate the hypertrophic cardiomyopathy phenotype of this disease[81]. "

    Full-text · Article · Jan 2016 · International Journal of Molecular Sciences
    • "Butyrate appears to be particularly effective when combined with the TGF-b and MAPK/ ERK pathway inhibitors (SB431542 and PD0325901, or others), which have previously been reported to aid iPSC reprogramming. Increased hiPSC reprogramming efficiency has also been achieved with the HDAC inhibitor trichostatin A (TSA) but with lower efficiency and greater toxicity than other HDAC inhibitors (Lin et al., 2009; Mali et al., 2010; Zhang and Wu, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) is a comprehensive epigenetic process involving genome-wide modifications of histones and DNA methylation. This process is often incomplete, which subsequently affects iPSC reprograming, pluripotency, and differentiation capacity. Here, we review the epigenetic changes with a focus on histone modification (methylation and acetylation) and DNA modification (methylation) during iPSC induction. We look at changes in specific epigenetic signatures, aberrations and epigenetic memory during reprogramming and small molecules influencing the epigenetic reprogramming of somatic cells. Finally, we discuss how to improve iPSC generation and pluripotency through epigenetic manipulations.
    No preview · Article · Oct 2015 · Journal of Genetics and Genomics
  • Source
    • "Combination of SB and PD, or SB, PD, and sodium butyrate (NAB) can convert partially reprogrammed colonies to a fully reprogrammed state, thereby improving the efficiency of reprogramming [18], [19]. Moreover, epigenetic modifier NAB is more reliable and efficient than VPA in generation of human iPS cells and contributes to more efficient reprogramming [20], [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Induced pluripotent stem (iPS) cells from somatic cells have great potential for regenerative medicine. The efficiency in generation of iPS cells has been significantly improved in recent years. However, the generation of high-quality iPS cells remains of high interest. Consistently, we demonstrate that knockout serum replacement (KSR)-based medium accelerates iPS cell induction and improves the quality of iPS cells, as confirmed by generation of chimeras and all iPS cell-derived offspring with germline transmission competency. Both alkaline phosphatase (AP) activity assay and expression of Nanog have been used to evaluate the efficiency of iPS cell induction and formation of ES/iPS cell colonies; however, appropriate expression of Nanog frequently indicates the quality of ES/iPS cells. Interestingly, whereas foetal bovine serum (FBS)-based media increase iPS cell colony formation, as revealed by AP activity, KSR-based media increase the frequency of iPS cell colony formation with Nanog expression. Furthermore, inhibition of MAPK/ERK by a specific inhibitor, PD0325901, in KSR- but not in FBS-based media significantly increases Nanog-GFP+ iPS cells. In contrast, addition of bFGF in KSR-based media decreases proportion of Nanog-GFP+ iPS cells. Remarkably, PD can rescue Nanog-GFP+ deficiency caused by bFGF. These data suggest that MAPK/ERK pathway influences high quality mouse iPS cells and that KSR- and PD-based media could enrich homogeneous authentic pluripotent stem cells.
    Full-text · Article · Aug 2014 · PLoS ONE
Show more